Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Sales from the neuroscience portfolio increased 19.9% to $2.51 billion, driven by higher sales of Botox Therapeutic, depression drug Vraylar, and migraine ... gained about 5% against the industry ...

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, expectations were $2.98. Operator: Good morning and thank you for standing by.

If the FDA does approve the drug, ubrogepant will however have to compete head-to-head against Eli Lilly ... with wrinkle treatment Botox - also used for migraine prevention - to drive take ...

Daw, 25, heads to Dallas this week for intricate surgery to address idiopathic condylar resorption, a degenerative and ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Botox is derived from botulinum toxin type A, a toxin that’s produced from the bacterium Clostridium botulinum. It just so ...